Meaney E, Gutiérrez-Salmeán G, Fanghaënel G, Sánchez L, Nájera N, Rivera JM, Alcocer A, Ceballos G

Language: English
References: 37
Page: 95-102
PDF size: 256.72 Kb.

Text Extraction

What’s in a name? –inquired young Juliet, the Shakespearian universal icon of passionate love. Then she herself answered: «that which we call a rose by any other name would smell as sweet», implying that doesn’t matter how we denominate things or persons, they are what they are intrinsically and not something else. While this assertion is probably true in poetry or drama, it is not equally accurate in science and medicine, which demand sharply precision of terms and proper use of them. The necessity of name things, persons or places has been an indispensable task, since the dawn of human history. In medicine (as in other fields of rational knowledge), common logic, as well as semantics and scientific language, need neat operational definitions to identify, classify, enclose, and restrict in recognizable segments, simple or complex biological and clinical concepts or phenomena. In this order of ideas, when we pronounce or write the term «diabetes mellitus type 2», everybody in every place, since a Nobel prize winner to the humblest third world physician, and from Alaska to Timbuktu, should have the same concept and the same understanding of what are we talking or writing about.

REFERENCES

1. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595-1607.

2. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res. 2004; 59: 207-223.

3. Kemp HG Jr. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol. 1973; 32: 375-376.

4. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De Sedibus et Causis Morborum per Anatomen Indagata’. Int J Obes. 2003; 27: 534-535.

5. Milici N. A short history of the metabolic syndrome definitions. Proc Rom Acad. Series B. 2010; 1: 13-20.

6. Lopes HF. l Corrêa-Giannella L, Consolim-Colombo FM, Egan BM. Visceral adiposity syndrome. Diabetol Metab Syndr. 2016; 8: 40.

7. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965; 1: 137.

8. Córdova-Pluma VH, Castro-Martínez G, Rubio-Guerra A, Hegewisch ME. Breve crónica de la definición del síndrome metabólico. Med Int Méx. 2014; 30: 312-328.

9. Haller H, Hanefeld M. Synoptische Betrachtung metabolischer Risikofaktoren. Haller H Hanefeld M Jaross W eds. Lipidstoffwechselstörungen. 1975; 254-264: Gustav Fischer Verlag Jena.

10. Meisinger C, Koletzko B, Heinrich J. Letter to the editor. Metabolic syndrome: Older than usually assumed, but still too young to die. Clin Chem. 2006; 52: 897-898.

11. Reaven GM. The metabolic syndrome: What’s in a name? Reply to: Meisinger et al. Metabolic syndrome: Older than usually assumed, but still too young to die. Clin Chem. 2006; 52: 898-899.

12. Falta W, Boller R. Insularer und insulinresistenter diabetes. Kkinische Wochenschrift. 1931; 10 (10): 438-443.

13. Reaven GM. Why syndrome X? Historical perspective from Harold Himsworth to the insulin resistance syndrome. Cell Metab. 2005; 1: 9-14.

14. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960; 39: 1157-1175.

15. Aronis KN, Mantzoros CS. A brief history of insulin resistance: from the first insulin radioimmunoassay to selectively targeting protein kinase C pathways. Metabolism. 2012; 61: 445-449.

16. Yalow RS, Berson SA. Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determinations by a new sensitive immuno-assay technic. Diabetes. 1960; 9: 254-260.

17. Myers MG Jr, White MF. The new elements of insulin signaling Insulin Receptor Substrate-1 and proteins with SH2 domains. Diabetes. 1993; 42: 643-650.

18. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989; 149: 1514-1520.

19. Zimmet P, Serjentson S, 1992. The epidemiology of diabetes mellitus and its relantionship with cardiovascular disease. New Apect in diabetes, Ed. Lefebvre & Standl de Gruyer, Berlin, 1992, 5-22.

20. Matsuzawa YM. Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev. 1997; 13: 3-13.

21. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000; 102: 179-184.

22. Foster DW. Insulin resistance–a secret killer? N Engl J Med. 1989; 320: 733-734.

23. Zambon A, Crepaldi G. The plurimetabolic syndrome: qualitative lipoprotein abnormalities and atherosclerosis. International Congress Series. 2003; 1253: 223-228.

24. Srivastava AK. Challenges in the treatment of cardiometabolic syndrome. Indian J Pharmacol. 2012; 44: 155-156.

25. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317: 350-335.

26. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992; 41: 715-722.

27. World Health Organization. Department of Noncommunicable Diseases Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. (last visit Jan 31, 2015) Available from: http:// www.whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf..

28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.

29. Grundy SM, Brewer B Jr, Cleeman JI, Smith SC Jr, Lenfant C, MD et al., for the Conference Participants. Definition of metabolic syndrome report of the national heart, lung, and blood institute/american heart association conference on scientific issues related to definition. Circulation. 2004; 109: 433-438.

30. Grundy SM. The metabolic syndrome still lives. Clin Chem. 2005; 51: 1352-1357.

31. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366: 1059-1062.

32. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005; 51: 931-938.

33. Grundy SM. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47: 1093-1100.

34. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645.

35. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341: 1097-1105.

36. Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y et al. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group III. Worldwide comorbidities of obesity. Circulation. 2004; 110: 476-483.

37. Sánchez-Castillo CP, Velázquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP; Encuesta Nacional de Salud (ENSA) 2000 Working Group. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res. 2003; 11: 442-451.